Drug reference

Eptifibatide

Antiplatelet · Antithrombotic, Antiplatelet

Also known as Integrilin

AntiplateletAntithrombotic, Antiplatelet

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk—no information available.

FDA category + note

Top interactionssee all 12 →

AbciximabSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AlteplaseSevereDatabaseDDInter
AnagrelideSevereDatabaseDDInter

Mechanism

Eptifibatide is a glycoprotein IIb/IIIa inhibitor that acts as an anti-integrin drug. It exerts its antiplatelet effects by preventing the binding of fibrinogen and von Willebrand factor to the glycoprotein IIb/IIIa receptor on the surface of platelets. This inhibition prevents platelet aggregation, thereby reducing the risk of thrombotic events.

Indications

In combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 24 hours (specialist use only)patients undergoing percutaneous coronary interventionmanagement of patients with non–ST-segment elevation acute coronary syndromeUnstable anginaCoronary angioplastyPatients undergoing PCI with a high coronary thrombus burden or thrombotic complications of PCI

Dosing

Adult: Initially 180 micrograms/kg by intravenous injection, then (by intravenous infusion) 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)
Renal adjustment: Avoid if eGFR less than 30 mL/minute/1.73 m2. Reduce infusion to 1 microgram/kg/minute if eGFR 30–50 mL/minute/1.73 m2
Hepatic adjustment: Manufacturer advises caution; avoid in significant impairment (increased risk of bleeding complications, limited information available)

Pharmacokinetics

Peak effect

Platelet inhibition reverses within 6–10 hours

Half-life

10 to 15 min (plasma)

Excretion

cleared by the kidneys

Contraindications

Abnormal bleeding within 30 days
Haemorrhagic diathesis
History of haemorrhagic stroke
Increased INR
Increased prothrombin time
Intracranial disease
Major surgery or severe trauma within 6 weeks
Severe hypertension
Stroke within last 30 days
Thrombocytopenia
renal failure

Side effects

Common

ArrhythmiasAtrioventricular blockCardiac arrestCongestive heart failureHaemorrhageHypotensionIntracranial haemorrhageProcedural complicationsShockbleeding

Serious